Loading...

Recursion Pharmaceuticals, Inc.

RXRX•NASDAQ
Healthcare
Biotechnology
$5.03
$-0.37(-6.85%)

Recursion Pharmaceuticals, Inc. (RXRX) Stock Overview

Explore Recursion Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.0/100

Key Financials

Market Cap2B
P/E Ratio-3.53
EPS (TTM)$-1.80
ROE-0.75%

AI Price Forecasts

1 Week$4.50
1 Month$4.05
3 Months$5.85
1 Year Target$7.66

RXRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Recursion Pharmaceuticals, Inc. (RXRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $7.66.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.53 and a market capitalization of 2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
32.00%
↑ 32.00%
Profit Growth
$-1.43
↓ 41.33%
EPS Growth
$-1.43
↓ 6.96%
Operating Margin
-960.64%
↓ 36.83%
ROE
-74.68%
↓ 41.33%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$6.00
Average$8.75
High$12.00

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CEO

Christopher C. Gibson

Employees

800

Headquarters

41 South Rio Grande Street, Salt Lake City, UT

Founded

2021

Frequently Asked Questions

;